Australian Prescriber最新文献_第3页

Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy. 马伐卡坦治疗症状性阻塞性肥厚性心肌病。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.006

引用次数: 0

Propranolol overdose following prescription for anxiety. 服用过量心得安治疗焦虑。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.005

Evan Browne, Jacqueline Huber, Bridin Murnion

引用次数: 0

Australian Prescriber: celebrating 50 years of growth and change. 澳大利亚处方：庆祝50年的成长和变化。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.007

Rosie Scott

引用次数: 0

New drug comments: aiming to deliver useful, timely, independent information for health professionals. 新药评论：旨在为卫生专业人员提供有用、及时、独立的信息。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.002

Tilenka Thynne, Rohan Elliott

引用次数: 0

Device-assisted therapies for Parkinson disease. 帕金森病的器械辅助疗法。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.003

Nadia Mouchaileh, Jillian Cameron

{"title":"Device-assisted therapies for Parkinson disease.","authors":"Nadia Mouchaileh, Jillian Cameron","doi":"10.18773/austprescr.003","DOIUrl":"10.18773/austprescr.003","url":null,"abstract":"Device-assisted therapies for Parkinson disease include apomorphine continuous subcutaneous infusion, levodopa continuous intestinal gel infusion, levodopa continuous subcutaneous infusion and deep brain stimulation. These therapies have a role in managing motor fluctuations and dyskinesias in people with advanced Parkinson disease when symptoms are inadequately controlled with oral and transdermal treatments. Subcutaneous infusion of apomorphine or levodopa are the least invasive device-assisted therapies. Levodopa intestinal infusion is delivered via a surgically placed intestinal tube. Deep brain stimulation involves implanting electrodes into specific target regions of the basal ganglia to modulate brain activity. Selecting an appropriate device-assisted therapy depends on individual factors such as age, comorbidities, symptom severity and patient preferences. Initiation and management require neurologist and multidisciplinary involvement, typically in a specialist movement disorder centre. Primary care clinicians play a crucial role in ongoing support and management for people using these therapies, including monitoring and managing adverse effects and communicating with movement disorder services.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 1","pages":"10-17"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Teclistamab for relapsed or refractory multiple myeloma. 替司他抗复发或难治性多发性骨髓瘤。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.001

引用次数: 0

Etrasimod for moderate to severe ulcerative colitis. 伊特拉西莫德用于中重度溃疡性结肠炎。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.004

引用次数: 0

Drug safety in pregnancy. 孕期用药安全。

IF 3.4

Australian Prescriber Pub Date : 2025-02-01 DOI: 10.18773/austprescr.2025.008

Debra Kennedy, Ronald Batagol

引用次数: 0

Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety? 澳大利亚的药物警戒：临床医生的不良事件报告如何促进药物和疫苗安全？

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.056

Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter

{"title":"Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?","authors":"Deborah Greenbaum, Stephanie Cheung, Claire Turner, Fiona Mackinnon, Claire Larter","doi":"10.18773/austprescr.2024.056","DOIUrl":"https://doi.org/10.18773/austprescr.2024.056","url":null,"abstract":"Reporting adverse events (adverse drug reactions) associated with medicines and vaccines assists with identifying previously unrecognised side effects and other safety concerns. Reporting adverse events to the Therapeutic Goods Administration is mandatory for sponsors (pharmaceutical companies), and strongly encouraged but voluntary for healthcare professionals and consumers. Adverse events should be reported even when causality is uncertain, as reports may contribute to identification of a safety signal for new or uncommon events. Suspected adverse events associated with new medicines and vaccines (registered in the last 5 years), and medicines included in the Black Triangle Scheme, should be prioritised for reporting. For other medicines, serious adverse events and unexpected adverse events should be prioritised. The Therapeutic Goods Administration analyses adverse event reporting data and uses signal detection methods to identify and evaluate emerging safety signals, which may lead to regulatory actions and communication to address safety issues.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"186-191"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic vapes for smoking cessation and nicotine dependence. 戒烟和尼古丁依赖的治疗性电子烟。

IF 3.4

Australian Prescriber Pub Date : 2024-12-01 DOI: 10.18773/austprescr.2024.054

Eileen Cole, Catherine Segan, Sacha Filia, Jennifer Kyi, Donita Baird

{"title":"Therapeutic vapes for smoking cessation and nicotine dependence.","authors":"Eileen Cole, Catherine Segan, Sacha Filia, Jennifer Kyi, Donita Baird","doi":"10.18773/austprescr.2024.054","DOIUrl":"https://doi.org/10.18773/austprescr.2024.054","url":null,"abstract":"The Australian Government has enacted laws restricting the supply of electronic cigarettes (vapes) to people requiring them for smoking cessation or the treatment of nicotine dependence, under the care of a medical practitioner, nurse practitioner or pharmacist. Currently no vapes are included on the Australian Register of Therapeutic Goods, meaning that the prescription and supply of therapeutic vapes must be through the Special Access Scheme or Authorised Prescriber pathways. Clinical guidelines state that therapeutic vapes may be considered for supporting people who have been unable to quit smoking using first-line therapies (a combination of behavioural support and registered nicotine replacement therapies or oral smoking cessation medicines). Clinical review should occur 1 week after vape initiation, with additional follow-up according to an individualised management plan, to monitor progress, review adverse effects (e.g. cough, irritated throat, headache or nausea), encourage the use of behavioural smoking cessation supports, and discourage dual use of vapes and conventional cigarettes. An attempt to wean or stop vaping after 12 weeks is recommended, with a possible transition to registered smoking cessation medicines if required (in addition to ongoing behavioural support). The maximum recommended duration of vape use is 12 months.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 6","pages":"171-176"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0